Shares of Allergy Therapeutics plc (LON:AGY – Get Free Report) reached a new 52-week high on Tuesday . The company traded as high as GBX 7 ($0.09) and last traded at GBX 6.53 ($0.08), with a volume of 2477185 shares trading hands. The stock had previously closed at GBX 6.80 ($0.09).
Allergy Therapeutics Price Performance
The company has a 50-day moving average price of GBX 5.61 and a 200-day moving average price of GBX 5.09. The firm has a market capitalization of £311.24 million, a P/E ratio of -108.75, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. The company has a debt-to-equity ratio of 37.22, a quick ratio of 1.48 and a current ratio of 1.40.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Read More
- Five stocks we like better than Allergy Therapeutics
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Stocks Helping to Bring AI to Healthcare
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- What is the Nasdaq? Complete Overview with History
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
